Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 1,810,000 shares, a growth of 145.8% from the January 15th total of 736,500 shares. Approximately 9.4% of the company’s stock are short sold. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 1.8 days.

Wall Street Analysts Forecast Growth

VIGL has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a report on Thursday, January 23rd. William Blair started coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating for the company. Wedbush upped their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vigil Neuroscience has a consensus rating of “Buy” and an average target price of $19.75.

Institutional Investors Weigh In On Vigil Neuroscience

A number of institutional investors have recently added to or reduced their stakes in the company. Walleye Capital LLC lifted its position in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after buying an additional 92,217 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Vigil Neuroscience during the third quarter valued at approximately $442,000. Blair William & Co. IL bought a new stake in Vigil Neuroscience during the fourth quarter worth $551,000. Geode Capital Management LLC boosted its position in Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after purchasing an additional 66,712 shares during the last quarter. Finally, abrdn plc bought a new position in Vigil Neuroscience in the 3rd quarter valued at $799,000. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Price Performance

NASDAQ VIGL opened at $2.69 on Thursday. The company has a fifty day moving average price of $2.04 and a 200-day moving average price of $2.95. The firm has a market cap of $109.97 million, a price-to-earnings ratio of -1.31 and a beta of 1.84. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.